Hope for celiac disease patients after years of avoiding gluten

First Traces Biotherapeutics announced promising preliminary results for an experimental drug called "ANP 033" aimed at treating celiac disease. The study, which involved 32 patients, showed that the medication reduced intestinal damage and symptoms caused by gluten exposure, with only 6% of those who received it needing symptom-relief drugs compared to 47% of those who took a placebo. Despite these encouraging results, experts emphasize that the drug is still in the early stages of testing, and larger studies are necessary to confirm its effectiveness and safety. For now, adhering to a gluten-free diet remains the primary treatment for celiac disease patients.